173 related articles for article (PubMed ID: 9364215)
1. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
[TBL] [Abstract][Full Text] [Related]
2. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity.
Aoki K; Yoshida T; Sugimura T; Terada M
Cancer Res; 1995 Sep; 55(17):3810-6. PubMed ID: 7641198
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
4. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA.
Nakano M; Aoki K; Matsumoto N; Ohnami S; Hatanaka K; Hibi T; Terada M; Yoshida T
Mol Ther; 2001 Apr; 3(4):491-9. PubMed ID: 11319909
[TBL] [Abstract][Full Text] [Related]
5. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells.
Zhu ZW; Friess H; Wang L; Bogardus T; Korc M; Kleeff J; Büchler MW
Clin Cancer Res; 2001 Jan; 7(1):105-12. PubMed ID: 11205897
[TBL] [Abstract][Full Text] [Related]
6. Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity.
Ohnami S; Matsumoto N; Nakano M; Aoki K; Nagasaki K; Sugimura T; Terada M; Yoshida T
Cancer Res; 1999 Nov; 59(21):5565-71. PubMed ID: 10554036
[TBL] [Abstract][Full Text] [Related]
7. The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma.
Cullen JJ; Weydert C; Hinkhouse MM; Ritchie J; Domann FE; Spitz D; Oberley LW
Cancer Res; 2003 Mar; 63(6):1297-303. PubMed ID: 12649190
[TBL] [Abstract][Full Text] [Related]
8. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA
Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity.
Miura Y; Ohnami S; Yoshida K; Ohashi M; Nakano M; Ohnami S; Fukuhara M; Yanagi K; Matsushita A; Uchida E; Asaka M; Yoshida T; Aoki K
Cancer Lett; 2005 Jan; 218(1):53-62. PubMed ID: 15639340
[TBL] [Abstract][Full Text] [Related]
10. G-rich oligonucleotide inhibits the binding of a nuclear protein to the Ki-ras promoter and strongly reduces cell growth in human carcinoma pancreatic cells.
Cogoi S; Quadrifoglio F; Xodo LE
Biochemistry; 2004 Mar; 43(9):2512-23. PubMed ID: 14992588
[TBL] [Abstract][Full Text] [Related]
11. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
[TBL] [Abstract][Full Text] [Related]
12. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis.
Lebedeva IV; Su ZZ; Sarkar D; Gopalkrishnan RV; Waxman S; Yacoub A; Dent P; Fisher PB
Oncogene; 2005 Jan; 24(4):585-96. PubMed ID: 15580305
[TBL] [Abstract][Full Text] [Related]
13. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.
Mohiuddin M; Chendil D; Dey S; Alcock RA; Regine W; Mohiuddin M; Ahmed MM
Anticancer Res; 2002; 22(2A):825-30. PubMed ID: 12014658
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
[TBL] [Abstract][Full Text] [Related]
16. Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth.
Kanovsky M; Michl J; Botzolaki G; Morin J; Kovac C; Chung DL; Chie L; Friedman FK; Pincus MR
Cancer Chemother Pharmacol; 2003 Sep; 52(3):202-8. PubMed ID: 12783204
[TBL] [Abstract][Full Text] [Related]
17. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.
Shichinohe T; Senmaru N; Furuuchi K; Ogiso Y; Ishikura H; Yoshiki T; Takahashi T; Kato H; Kuzumaki N
J Surg Res; 1996 Dec; 66(2):125-30. PubMed ID: 9024823
[TBL] [Abstract][Full Text] [Related]
18. [The study of the effect of antisense oligonucleotide specific to K-ras point mutation on human pancreatic carcinoma cell PC-2].
Wang YX; Gao L; Ji ZZ
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(21):1387-90. PubMed ID: 16318775
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.
Hatanaka K; Suzuki K; Miura Y; Yoshida K; Ohnami S; Kitade Y; Yoshida T; Aoki K
J Gene Med; 2004 Oct; 6(10):1139-48. PubMed ID: 15452878
[TBL] [Abstract][Full Text] [Related]
20. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
Jin K; Park S; Ewton DZ; Friedman E
Cancer Res; 2007 Aug; 67(15):7247-55. PubMed ID: 17671193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
